U.S. markets open in 5 hours
  • S&P Futures

    4,241.25
    +5.00 (+0.12%)
     
  • Dow Futures

    33,908.00
    +73.00 (+0.22%)
     
  • Nasdaq Futures

    14,273.75
    +15.50 (+0.11%)
     
  • Russell 2000 Futures

    2,294.60
    +2.10 (+0.09%)
     
  • Crude Oil

    73.54
    +0.69 (+0.95%)
     
  • Gold

    1,784.30
    +6.90 (+0.39%)
     
  • Silver

    26.06
    +0.20 (+0.79%)
     
  • EUR/USD

    1.1945
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    1.4720
    0.0000 (0.00%)
     
  • Vix

    16.42
    -1.47 (-8.22%)
     
  • GBP/USD

    1.3973
    +0.0026 (+0.19%)
     
  • USD/JPY

    110.8770
    +0.2420 (+0.22%)
     
  • BTC-USD

    34,158.23
    +2,044.27 (+6.37%)
     
  • CMC Crypto 200

    818.70
    +24.37 (+3.07%)
     
  • FTSE 100

    7,091.26
    +1.25 (+0.02%)
     
  • Nikkei 225

    28,874.89
    -9.24 (-0.03%)
     

Viracta Therapeutics to Present at the Jefferies Virtual Healthcare Conference

·1 min read

SAN DIEGO, May 27, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that Company management will present at the Jefferies Virtual Healthcare Conference taking place June 1-4, 2021. The Company will also participate in one-on-one investor meetings at the conference.

Details on the presentation can be found below.

Date:

Thursday, June 3, 2021

Time:

2:30 PM ET

Format:

Corporate presentation

Webcast:

https://wsw.com/webcast/jeff174/virx/1890351

A replay of the presentation will be available on the "Events and Webcasts" section of the Viracta website at https://viracta.investorroom.com/events-and-webcasts#past.

About Viracta Therapeutics, Inc.
Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.

For additional information please visit www.viracta.com.

Investor Relations Contact:

Company Contact:

Joyce Allaire

Dan Chevallard

LifeSci Advisors

Chief Operating Officer and Chief Financial Officer

jallaire@lifesciadvisors.com

dchevallard@viracta.com

(212) 915-2569

(858) 771-4193

Viracta Therapeutics, Inc. Logo (PRNewsfoto/Viracta Therapeutics, Inc.)
Viracta Therapeutics, Inc. Logo (PRNewsfoto/Viracta Therapeutics, Inc.)
Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/viracta-therapeutics-to-present-at-the-jefferies-virtual-healthcare-conference-301301289.html

SOURCE Viracta Therapeutics, Inc.